Svenson Morten, Jacobi Henrik H, Bødtger Uffe, Poulsen Lars K, Rieneck Klaus, Bendtzen Klaus
Institute for Inflammation Research, Rigshospitalet University Hospital, Blegdamsvej 9, Copenhagen DK-2100, Denmark.
Mol Immunol. 2003 Jan;39(10):603-12. doi: 10.1016/s0161-5890(02)00198-0.
Specific allergy vaccination (SAV) is associated with increased levels of allergen specific IgG in serum. It is not clear, however, to what extent qualitative changes in allergen binding to IgG may be induced as well. We therefore analyzed the binding of the major allergen in pollen of birch (Betula verrucosa) (Bet v 1), the major allergen in birch pollen, to serum IgG and IgE, separately and in competition. Sera from six birch pollen-allergic patients were obtained before and after 5 years of SAV, and binding was assessed with 125I-Bet v 1. Before SAV, IgG bound more than eight times the amount of Bet v 1 compared with IgE, and together they accounted for more than 85% of the serum binding capacity. While SAV induced minimal changes in IgE binding, the IgG binding capacities increased 6-32 times. In contrast, the binding avidities (K(d) 28-40pM) changed less than 20%, pre- and post-SAV IgG provided similar inhibition of Bet v 1 binding to IgE at equimolar levels, and cross inhibition studies between IgG and IgE showed low inter-individual differences. Following SAV, all sera reduced Bet v 1 binding to CD23(+) cells, correlating with reduced binding of Bet v 1 to IgE (P<0.001). These results show that high avidity IgG of low inter-individual difference in Bet v 1 binding quality is the dominant binding factor of Bet v 1 in sera of birch pollen-allergic patients, and that SAV-induced inhibition of binding of Bet v 1 to IgE can be explained mainly or solely by increased amounts of IgG.
特异性变应原疫苗接种(SAV)与血清中变应原特异性IgG水平升高有关。然而,尚不清楚变应原与IgG结合的定性变化在多大程度上也可能被诱导。因此,我们分别分析了桦树(疣枝桦)花粉中的主要变应原(Bet v 1)与血清IgG和IgE的结合情况,以及它们之间的竞争结合情况。采集了6名桦树花粉过敏患者在接受SAV治疗5年前后的血清,并用125I-Bet v 1评估结合情况。在接受SAV治疗前,与IgE相比,IgG结合的Bet v 1量是其8倍多,二者共同占血清结合能力的85%以上。虽然SAV诱导的IgE结合变化极小,但IgG结合能力增加了6至32倍。相比之下,结合亲和力(K(d)为28 - 40pM)变化小于20%,SAV治疗前后的IgG在等摩尔水平下对Bet v 1与IgE结合的抑制作用相似,并且IgG和IgE之间的交叉抑制研究显示个体间差异较小。接受SAV治疗后,所有血清均降低了Bet v 1与CD23(+)细胞的结合,这与Bet v 1与IgE结合的减少相关(P<0.001)。这些结果表明,在Bet v 1结合质量方面个体间差异较小的高亲和力IgG是桦树花粉过敏患者血清中Bet v 1的主要结合因子,并且SAV诱导的Bet v 1与IgE结合的抑制作用主要或完全可以由IgG量的增加来解释。